Literature DB >> 33622073

Bidirectional Correlations Between Dopaminergic Function and Motivation in Parkinson's Disease.

Jared T Hinkle1, Kelly A Mills2, Kate Perepezko3, Gregory M Pontone4.   

Abstract

OBJECTIVE: To test the hypothesis that striatal dopamine function influences motivational alterations in Parkinson disease (PD), we compared vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DaT) imaging data in PD patients with impulse control disorders (ICDs), apathy, or neither.
METHODS: We extracted striatal binding ratios (SBR) from VMAT2 PET imaging (18F-AV133) and DaTscans from the Parkinson's Progression Markers Initiative (PPMI) multicenter observational study. Apathy and ICDs were assessed using the Movement Disorders Society-revised Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), respectively. We used analysis of variance (ANOVA) and log-linear mixed-effects (LME) regression to model SBRs with neurobehavioral metrics.
RESULTS: Among 23 participants (mean age 62.7 years, mean disease duration 1.8 years) with VMAT2 imaging data, 5 had apathy, 5 had an ICD, and 13 had neither. ANOVA indicated strong groupwise differences in VMAT2 binding in right anterior putamen [F(2,20) = 16.2, p < 0.0001), right posterior putamen [F(2,20) = 16.9, p < 0.0001), and right caudate [F(2,20) = 6.8, p = 0.006)]. Post-hoc tests and repeated-measures analysis with LME regression also supported right striatal VMAT2 elevation in the ICD group and reduction in the apathy group relative to the group with neither ICD nor apathy. DaT did not exhibit similar correlations, but normalizing VMAT2 with DaT SBR strengthened bidirectional correlations with ICD (high VMAT2/DaT) and apathy (low VMAT2/DaT) in all striatal regions bilaterally.
CONCLUSIONS: Our findings constitute preliminary evidence that striatal presynaptic dopaminergic function helps describe the neurobiological basis of motivational dysregulation in PD, from high in ICDs to low in apathy.

Entities:  

Keywords:  PPMI; Parkinson’s disease; VMAT2; apathy; biomarkers; dopamine; dopamine transporter; geriatric psychiatry; impulse control disorders; motivation; movement disorder; neuropsychological testing

Mesh:

Substances:

Year:  2021        PMID: 33622073      PMCID: PMC8382801          DOI: 10.1177/0891988721996802

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  44 in total

1.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.

Authors:  T S Benamer; J Patterson; D G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H Horstink; H J Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

2.  Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.

Authors:  Ramachandiran Nandhagopal; Lisa Kuramoto; Michael Schulzer; Edwin Mak; Jacqueline Cragg; Jess McKenzie; Siobhan McCormick; Thomas J Ruth; Vesna Sossi; Raul de la Fuente-Fernandez; A Jon Stoessl
Journal:  Brain       Date:  2011-11       Impact factor: 13.501

Review 3.  Dopamine, learning and motivation.

Authors:  Roy A Wise
Journal:  Nat Rev Neurosci       Date:  2004-06       Impact factor: 34.870

Review 4.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

Authors:  K Ray Chaudhuri; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

5.  Dissociable roles of ventral and dorsal striatum in instrumental conditioning.

Authors:  John O'Doherty; Peter Dayan; Johannes Schultz; Ralf Deichmann; Karl Friston; Raymond J Dolan
Journal:  Science       Date:  2004-04-16       Impact factor: 47.728

6.  Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.

Authors:  Daniel Weintraub; Staci Hoops; Judy A Shea; Kelly E Lyons; Rajesh Pahwa; Erika D Driver-Dunckley; Charles H Adler; Marc N Potenza; Janis Miyasaki; Andrew D Siderowf; John E Duda; Howard I Hurtig; Amy Colcher; Stacy S Horn; Matthew B Stern; Valerie Voon
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

7.  Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.

Authors:  G Drui; S Carnicella; C Carcenac; M Favier; A Bertrand; S Boulet; M Savasta
Journal:  Mol Psychiatry       Date:  2013-02-12       Impact factor: 15.992

8.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

9.  Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease.

Authors:  Chris Vriend; Anna H Nordbeck; Jan Booij; Ysbrand D van der Werf; Tommy Pattij; Pieter Voorn; Pieter Raijmakers; Elisabeth M J Foncke; Elsmarieke van de Giessen; Henk W Berendse; Odile A van den Heuvel
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

10.  Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations.

Authors:  Jessie Fanglu Fu; Ivan Klyuzhin; Jessamyn McKenzie; Nicole Neilson; Elham Shahinfard; Katie Dinelle; Martin J McKeown; A Jon Stoessl; Vesna Sossi
Journal:  Neuroimage Clin       Date:  2019-05-08       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.